Fig. 1From: Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancerDifferences in PSA kinetics between cases treated by MAB + EBRT and MAB + EBRT + PPB combination therapies. a PSA nadir. b Time to PSA nadir. c PSA doubling time. d Declining extent of PSABack to article page